Hiromitsu Kumada Selected Research

Protease Inhibitors (Protease Inhibitor)

12/2022	Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
1/2018	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
1/2017	Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
1/2016	Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
7/2015	High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
5/2015	Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
1/2014	A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
4/2013	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
8/2012	Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
7/2011	Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiromitsu Kumada Research Topics

Disease

124	Hepatocellular Carcinoma (Hepatoma) 12/2023 - 01/2002
113	Infections 10/2022 - 01/2002
92	Chronic Hepatitis C 10/2022 - 01/2002
76	Fibrosis (Cirrhosis) 12/2022 - 01/2002
71	Chronic Hepatitis B 10/2023 - 01/2002
42	Liver Cirrhosis (Hepatic Cirrhosis) 09/2021 - 01/2002
40	Neoplasms (Cancer) 01/2023 - 01/2003
35	Hepatitis 05/2014 - 01/2002
28	Liver Diseases (Liver Disease) 01/2024 - 01/2002
24	Hepatitis B 01/2022 - 01/2002
23	Hepatitis C 07/2018 - 09/2005
20	Non-alcoholic Fatty Liver Disease 07/2023 - 01/2009
20	Chronic Hepatitis (Chronic Active Hepatitis) 03/2014 - 01/2002
16	Liver Neoplasms (Liver Cancer) 07/2023 - 07/2006
14	Anemia 01/2017 - 07/2004
13	Carcinogenesis 01/2014 - 01/2003
11	Diabetes Mellitus 07/2023 - 07/2006
11	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2009
11	Body Weight (Weight, Body) 01/2021 - 10/2007
7	Disease Progression 09/2023 - 01/2004
7	Virus Diseases (Viral Diseases) 04/2021 - 04/2003
6	Headache (Headaches) 10/2016 - 03/2012
6	Persistent Infection 10/2013 - 05/2004
5	Hypertension (High Blood Pressure) 12/2023 - 09/2009
5	Fever (Fevers) 10/2022 - 03/2012
5	Insulin Resistance 01/2022 - 06/2009
5	Viremia 01/2017 - 01/2007
4	Hepatic Encephalopathy 12/2023 - 10/2004
4	Inflammation (Inflammations) 04/2022 - 01/2012
4	Pruritus (Itching) 09/2018 - 10/2016
4	Diarrhea 04/2016 - 03/2012
3	Fatty Liver 04/2022 - 09/2009

Drug/Important Bio-Agent (IBA)

110	InterferonsIBA 12/2020 - 01/2002
78	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 01/2002
45	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2003
45	Lamivudine (Epivir)FDA Link 05/2017 - 01/2002
37	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
31	Hepatitis B e AntigensIBA 01/2024 - 01/2002
28	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 02/2002
21	Hepatitis B Surface Antigens (HBsAg)FDA Link 10/2023 - 01/2002
21	daclatasvirIBA 01/2020 - 03/2012
21	Alanine Transaminase (SGPT)IBA 09/2017 - 01/2003
19	entecavir FDA Link 01/2022 - 06/2007
18	lenvatinibIBA 12/2023 - 03/2016
17	AntigensIBA 01/2022 - 01/2002
16	asunaprevirIBA 01/2020 - 03/2012
15	telaprevirIBA 02/2018 - 01/2010
14	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2020 - 01/2003
14	Transaminases (Aminotransferases)IBA 02/2015 - 01/2003
13	Amino Acids FDA Link 09/2015 - 08/2008
11	Protease Inhibitors (Protease Inhibitor)IBA 12/2022 - 01/2010
11	Proteins (Proteins, Gene)FDA Link 10/2022 - 03/2006
11	Serum AlbuminIBA 10/2017 - 07/2005
10	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2023 - 08/2008
10	BilirubinIBA 10/2017 - 01/2003
9	glecaprevir and pibrentasvirIBA 12/2022 - 01/2018
9	Biomarkers (Surrogate Marker)IBA 04/2022 - 12/2007
9	miriplatinIBA 02/2018 - 01/2011
9	Interferon-alpha (Interferon Alfa)IBA 05/2014 - 02/2002
8	adefovir dipivoxil (Hepsera)FDA Link 06/2014 - 01/2004
7	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 03/2015 - 01/2006
7	Interferon-betaIBA 01/2011 - 01/2008
6	Hemoglobins (Hemoglobin)IBA 07/2023 - 11/2004
6	lipoarabinomannan (LAM)IBA 05/2017 - 12/2007
6	AlbuminsIBA 02/2015 - 01/2009
6	adefovirIBA 06/2014 - 01/2004
5	Tenofovir (Viread)FDA Link 12/2021 - 01/2014
5	Fetal Proteins (Fetoprotein)IBA 04/2021 - 09/2013
5	ombitasvirIBA 04/2018 - 05/2015
5	paritaprevirIBA 04/2018 - 05/2015
5	Ritonavir (Norvir)FDA Link 04/2018 - 05/2015
5	NucleosidesIBA 05/2017 - 06/2007
5	PlatinumIBA 03/2013 - 04/2009
4	Cell-Free Nucleic AcidsIBA 01/2023 - 12/2020
4	SofosbuvirIBA 10/2022 - 01/2017
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022 - 02/2002
4	NucleotidesIBA 02/2022 - 09/2004
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2017
4	Sorafenib (BAY 43-9006)FDA Link 02/2021 - 09/2011
4	Glucose (Dextrose)FDA LinkGeneric 02/2020 - 06/2012
4	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamideIBA 01/2020 - 03/2017
4	grazoprevirIBA 01/2020 - 04/2017
4	elbasvirIBA 01/2020 - 04/2017
4	P-300IBA 08/2019 - 01/2018
4	SimeprevirIBA 01/2017 - 05/2014
4	Branched-Chain Amino AcidsIBA 05/2013 - 07/2005
4	Aspartic Acid (Aspartate)FDA Link 04/2010 - 05/2004
3	Tumor Biomarkers (Tumor Markers)IBA 04/2022 - 01/2008
3	CanagliflozinIBA 01/2022 - 05/2019
3	Circular DNAIBA 01/2022 - 01/2009
3	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2002
3	Peptides (Polypeptides)IBA 09/2021 - 09/2008

Therapy/Procedure

189	Therapeutics 12/2023 - 01/2002
19	Radiofrequency Ablation 02/2019 - 01/2002
10	Drug Tapering 01/2017 - 07/2004
9	Hepatectomy 10/2020 - 12/2013
8	Drug Therapy (Chemotherapy) 09/2023 - 11/2011
6	Aftercare (After-Treatment) 02/2021 - 12/2006
5	Retreatment 03/2019 - 04/2003
4	Duration of Therapy 01/2018 - 01/2010